AG真人官方

Kura Sushi USA (NASDAQ: KRUS) filed its fiscal Q3 2025 Form 10-Q for the quarter ended 31 May 2025. The company now operates 76 restaurants, up from 63 a year ago, and plans to reach 79-81 units by fiscal year-end. Expansion, menu price increases and new store openings drove a 17.3 % year-over-year (YoY) sales increase to $74.0 million. Despite negative traffic, Q3 comparable restaurant sales fell only 2.1 % thanks to a 0.8-point price/mix benefit.

Profitability improved markedly. Q3 produced net income of $0.6 million (diluted EPS $0.05) versus a $0.6 million loss in the prior-year period. Restaurant-level operating profit reached $13.5 million (18.2 % margin), while corporate G&A leverage and lower litigation expense helped narrow the operating loss to $0.2 million. Nine-month results remain negative, however, with a $4.2 million net loss on $203.3 million of sales (+18.3 % YoY).

Cost dynamics:

• Food & beverage costs fell 90 bp YoY to 28.3 % of sales on pricing and supply-chain initiatives.
• Labor rose 50 bp to 33.1 % of sales as wage inflation outpaced price actions.
• Occupancy expense climbed to 7.5 % of sales, reflecting new unit leases.

Balance sheet strength. A November 2024 follow-on equity offering added $64.4 million net, boosting cash and marketable securities to $92.9 million (cash $47.1 m; ST investments $13.4 m; LT investments $32.5 m). The company has no debt and an undrawn $45 million revolver with parent Kura Japan. Total assets rose to $419.4 million, with lease liabilities of $166.0 million (current and long-term).

Cash flow & capex. Operating cash flow was $15.3 million YTD. Heavy new-unit build-out drove $84.2 million of investing outflows (capex $37 million; securities purchases $70 million). Net cash decreased $3.9 million, but liquidity remains ample.

Legal & risk items. The company incurred $5.1 million in wage-and-hour settlements and faces an unresolved California labor class action. Management believes additional losses are not yet estimable. New FASB disclosure standards (ASU 2023-07, 2023-09, 2024-03) will be adopted between fiscal 2025-2028.

Outlook. Management targets 15 total openings in fiscal 2025, implying two more restaurants in Q4. It expects continued revenue growth but also higher operating costs (labor, utilities, occupancy). No quantitative guidance was provided.

Hims & Hers Health, Inc. (HIMS) 鈥� Form 4 insider transaction

Chief Legal Officer Soleil Boughton filed a Form 4 reporting the sale of 2,572 Class A common shares on 30 Jun 2025 under a previously established Rule 10b5-1 trading plan adopted 28 Aug 2024. The shares were sold at a stated price of $50.50 each (transaction code 鈥淪鈥�), reducing Boughton鈥檚 directly held position to 160,737 shares. No derivative securities were involved and no additional acquisitions were reported.

The transaction represents roughly 1.6 % of the officer鈥檚 post-transaction holdings and generated proceeds of approximately $129 k. Because the sale was executed pursuant to a 10b5-1 plan, it is generally viewed as pre-scheduled rather than opportunistic. No other executives or directors were listed on this filing.

From a governance perspective, the filing signals routine portfolio diversification rather than a material change in insider sentiment. Investors may monitor future filings for patterns or larger-scale disposals, but this single, modest sale is unlikely to alter the fundamental investment thesis for HIMS.

Franklin Financial Services Corporation (FRAF) filed a Form 4 disclosing that director Daniel J. Fisher acquired 313 common shares on 06/23/2025 at an implied price of $34.60 per share, totaling roughly $10.8 thousand. The shares were issued in lieu of cash compensation for a portion of Fisher鈥檚 board fees. Following the transaction, Fisher directly owns 29,276 shares, a figure that includes previously reported unvested restricted stock units. No derivative securities were involved.

The filing represents a routine compensation-related share issuance rather than an open-market purchase, but it still modestly increases insider equity alignment without altering control dynamics or signaling material changes to FRAF鈥檚 capital structure.

Hims & Hers Health (HIMS) Chief Financial Officer Oluyemi Okupe executed a planned sale of 23,107 shares of Class A Common Stock on June 23, 2025, at an average weighted price of $47.2483 per share (range: $47.15 - $47.43).

Following the transaction, Okupe's holdings include:

• 63,222 shares held directly
• 70,575 shares held indirectly through the Oluyemi Okupe Separate Property Trust

The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2024, demonstrating pre-planned, compliant insider trading activity. This transaction represents a partial reduction of the CFO's direct holdings while maintaining significant equity stake in the company through both direct and trust ownership.

A Form 144 filing from Hims & Hers Health reveals a proposed sale of 69,431 shares of common stock with an aggregate market value of $2,914,713.38. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 23, 2025.

The securities being sold were acquired through multiple compensation events:

• 37,186 shares from stock options (February 2022)
• 9,138 RSUs (June 2024)
• 23,107 RSUs (June 2025, across three grants)

The filing also discloses previous sales by Oluyemi Okupe over the past 3 months, totaling approximately 45,923 shares between April-May 2025, with total gross proceeds of about $1.98 million. These transactions demonstrate a consistent pattern of insider sales, with most individual transactions ranging from ~1,000 to ~9,200 shares.